The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.
Our Vision: Educate | Inform | Advocate
Second Global Summit on Precision Diagnosis for Prostate Cancer
Friday, October 13-Saturday, October 14, 2017
Sheraton Boston, Boston, MA – View the Summit program.
Five Facts about Prostate Cancer
1PrevalenceProstate cancer is the most common (non-skin) cancer in American men, representing 33% of all new cases.
2Prostate cancer affects 1 in 7 men.1 in 7 men will be diagnosed with prostate cancer during their lifetime. In 2015, nearly 6,000 men were diagnosed with prostate cancer in Massachusetts, with an incidence rate of 4%-6% higher than the national average.
3Second leading cause of cancer death in men.Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
4Prostate cancer top risk factors.
African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.
Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
5This year over 27,000 men will die of prostate cancer.
Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.5 million men in the United States who have been diagnosed with prostate cancer are still alive today.
Statistics from The American Cancer Society 2017
We need your support! Become a Member or Donate to MPCC today.
Save the Date:
ZERO Prostate Cancer Run/Walk — Sunday, September 10, 9:00AM, Newton City Hall (learn more here)
21st Annual Prostate Cancer Symposium — May 4, 2018, Newton Marriott, Newton, MA
Sarm Prostate Cancer Study at Brigham and Women’s Hospital — Go here to learn more.
“I’ve never understood why men don’t talk about it. A couple of men I know who had prostate cancer, as far as them coming together — nobody talks about it. There are times men are bragging, you know, on this subject, but now it’s just total silence,” says “Joe” (not his real name) of Oxnard,.. read more →
Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. Read more read more →